Sanofi (SNYNF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous Close | 100.50 |
| Open | 100.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 100.50 - 100.50 |
| 52 Week Range | 91.55 - 114.80 |
| Volume | |
| Avg. Volume | 13,893 |
| Market Cap | 125.669B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 18.72 |
| EPS (TTM) | 5.37 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.52 (3.50%) |
| Ex-Dividend Date | May 06, 2022 |
| 1y Target Est | N/A |
- GlobeNewswire
Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China Collaboration to accelerate the development and access of oncology medicines for cancer patients in ChinaClinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent solid tumors in China Sanofi to make an initial equity investment of €300 million
- Zacks
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
© 2022 Yahoo. All rights reserved.
